Christopher Gibson, Director at RECURSION PHARMACEUTICALS, INC. (RXRX), sold 40,000 shares at $3.10 ($124K) on 2026-04-07, disclosed to the SEC on 2026-04-08.
Scheduled sale ($124k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RXRX | SELL | 2026-05-08 | $135K | — | Filing → |
| RXRX | SELL | 2026-04-24 | $144K | — | Filing → |
| RXRX | SELL | 2026-03-25 | $130K | — | Filing → |